



---

PANEL SESSION 4 – Tuesday June 9, 2026 | 5.45pm – 6.45pm

---

[PN25 – Beyond The Guidelines: Uncovering Hidden Realities Of Procedural And Organizational Health Technology Assessment Practices](#)

**Contributors:** Erik Elliott, Wim Goettsch, Katarina Beravs Bervar, Michal Stanak

**Summary:** While formal methodological guidelines are published for health technology assessment (HTA) agencies, the informal procedural and organizational features of their operation are not well documented in the public domain. This panel aims to shed light on key considerations for developing HTA agencies to structure their internal processes, via a presentation of research, expert panellists, and engaging discussion with attendees.

[PN26 – From Evidence To Impact: Leveraging Health Technology Assessment To Shape Pluralistic Health Systems In India And Brazil](#)

**Contributors:** Abha Mehndiratta, Luciene Fontes Schluckebier Bonan, Michael Drummond, Somen Saha

**Summary:** This interactive panel explores how Health Technology Assessment (HTA) can drive evidence-informed change in pluralistic health systems, drawing lessons from Brazil and India. Through case presentations, comparative discussion, and audience engagement, the session will examine governance, coordination, capability building, and stakeholder engagement approaches to strengthen HTA's legitimacy, uptake, and impact across diverse, multi-level systems.

[PN28 – Helping Or Hurting Health Technology Assessments? When Is Transportability An Appropriate Solution When Local Real-World Evidence Is Limited?](#)

**Contributors:** Uwe Siebert, Philani Mpofo, Lindsey Power-Happ, Grammati Sarri

**Summary:** When local data are limited, HTA bodies face a critical challenge of reliably applying international evidence. Transportability offers a solution, but its growing use highlights the need for robust frameworks and methodological guidelines. This session will explore these challenges, with panelists discussing what standards, assumptions, and best practices are required to determine when transportability succeeds, and when it falls short.

[PN29 – How Can Artificial Intelligence Health Technologies Be Scientifically Evaluated? Health Technology Assessment Perspective From Selected Countries](#)

**Contributors:** Lizheng Shi, Yingyao Chen, Tracy Merlin, Jeonghoon Ahn

**Summary:** Artificial intelligence (AI) health technologies present unique evaluation challenges for health technology assessment (HTA). This panel compares HTA frameworks for AI from selected countries, directly addressing how HTA methodological innovation for AI is utilized and how HTA is adapting to



shape tomorrow's health systems. The session aims to foster international collaboration to advance robust evaluation methodologies for transformative AI technologies.

### [PN30 – Integrating Equity Into Health Technology Assessment: Lessons From The Latin America Policy Forum](#)

**Contributors:** Sebastian Garcia Marti, Vania Canuto, Eva Maria Cruz de Castilla, Alicia Granados  
**Summary:** Equity is increasingly recognized as a core pillar of fair and legitimate health decision-making yet remains insufficiently integrated into Health Technology Assessment (HTA), particularly in Latin America. Building on the 2025 HTAi LATAM Policy Forum, where 55 stakeholders from 15 countries examined ways to incorporate equity into HTA, this panel will present key findings, conceptual developments, priority dimensions, and actionable guidance for agencies seeking structured, feasible approaches to address the incorporation of equity in HTA processes.

### [PN31 – Towards A Sustainable Dialogue Between HTA Bodies And Academia: The SUSTAIN-DIALOGUE Initiative](#)

**Contributors:** Carlo Federici, Vivian Reckers-Droog, Saskia Knies, Tomas Tesař  
**Summary:** This session presents the SUSTAIN-DIALOGUE initiative under SUSTAIN-HTA, aiming to establish a lasting, structured dialogue between HTA bodies and academia across Europe. It will explore barriers, enablers, and strategies for collaboration, featuring academic and HTA perspectives, and interactive discussions to identify next steps for integrating SUSTAIN-DIALOGUE into the HTA landscape and strengthening communication across HTA bodies.

### [PN32 – Women’s Health And Equity Frameworks: The Potential Of HTA For Gender-Transformative Health Systems](#)

**Contributors:** Elena Petelos, Sophie Söderholm Werkö, Wija Oortwijn  
**Summary:** Emerging technologies impact women’s health and wellbeing, yet weak equity frameworks, gender bias, and under- representation worsen disparities. HTA can strengthen evidence, policy, and system decisions for women’s autonomy, access, and quality of care. This panel examines gender-responsive HTA approaches, addressing social determinants and intersectionality to empower underrepresented voices, increase inclusion and promote equitable adoption of innovative health technologies.

### [PN37 – Lessons Learned from the First Joint Clinical Assessments: Relevance for National HTA in the EU and Beyond](#)

**Contributors:** Beate Wieseler, Emer Fogarty, Anne Willemsen, Alima Almadiyeva  
**Summary:** Since January 2025, European Member States jointly assess drugs under the European Health Technology Assessment (HTA) Regulation. The session will present and discuss the Joint Clinical



Assessment (JCA) of tovorafenib which will be among the first JCAs to be finalised. The discussion will address how the results of this initial assessment fit into the wider framework of European HTA but also its impact on the national HTA outside the EU.